136 related articles for article (PubMed ID: 9562602)
21. Small molecule antagonists of integrin receptors.
Perdih A; Dolenc MS
Curr Med Chem; 2010; 17(22):2371-92. PubMed ID: 20491638
[TBL] [Abstract][Full Text] [Related]
22. Diamine containing VLA-4 antagonists.
Astles PC; Harris NV; Morley AD
Bioorg Med Chem; 2001 Aug; 9(8):2195-202. PubMed ID: 11504657
[TBL] [Abstract][Full Text] [Related]
23. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
[TBL] [Abstract][Full Text] [Related]
24. The Design of Potent, Selective and Drug-Like RGD αvβ1 Small-Molecule Inhibitors Derived from non-RGD α4β1 Antagonists.
Hatley RJD; Barrett TN; Slack RJ; Watson ME; Baillache DJ; Gruszka A; Washio Y; Rowedder JE; Pogány P; Pal S; Macdonald SJF
ChemMedChem; 2019 Jul; 14(14):1315-1320. PubMed ID: 31207080
[TBL] [Abstract][Full Text] [Related]
25. Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.
Archibald SC; Head JC; Gozzard N; Howat DW; Parton TA; Porter JR; Robinson MK; Shock A; Warrellow GJ; Abraham WM
Bioorg Med Chem Lett; 2000 May; 10(9):997-9. PubMed ID: 10853677
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator inhibits alpha 4 beta 1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity.
Olivier P; Bieler G; Müller KM; Hauzenberger D; Rüegg C
Eur J Immunol; 1999 Oct; 29(10):3196-209. PubMed ID: 10540331
[TBL] [Abstract][Full Text] [Related]
27. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Perron-Sierra F; Saint Dizier D; Bertrand M; Genton A; Tucker GC; Casara P
Bioorg Med Chem Lett; 2002 Nov; 12(22):3291-6. PubMed ID: 12392735
[TBL] [Abstract][Full Text] [Related]
28. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.
Fisher MJ; Gunn B; Harms CS; Kline AD; Mullaney JT; Nunes A; Scarborough RM; Arfsten AE; Skelton MA; Um SL; Utterback BG; Jakubowski JA
J Med Chem; 1997 Jun; 40(13):2085-101. PubMed ID: 9207949
[TBL] [Abstract][Full Text] [Related]
29. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
Hoffmann S; He S; Jin M; Ehren M; Wiedemann P; Ryan SJ; Hinton DR
BMC Ophthalmol; 2005 Jun; 5():16. PubMed ID: 15987521
[TBL] [Abstract][Full Text] [Related]
30. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.
Engleman VW; Nickols GA; Ross FP; Horton MA; Griggs DW; Settle SL; Ruminski PG; Teitelbaum SL
J Clin Invest; 1997 May; 99(9):2284-92. PubMed ID: 9151803
[TBL] [Abstract][Full Text] [Related]
31. The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Chang LL; Truong Q; Mumford RA; Egger LA; Kidambi U; Lyons K; McCauley E; Van Riper G; Vincent S; Schmidt JA; MacCoss M; Hagmann WK
Bioorg Med Chem Lett; 2002 Jan; 12(2):159-63. PubMed ID: 11755344
[TBL] [Abstract][Full Text] [Related]
32. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
33. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
[TBL] [Abstract][Full Text] [Related]
34. Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha4beta1: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes.
Newham P; Craig SE; Clark K; Mould AP; Humphries MJ
J Immunol; 1998 May; 160(9):4508-17. PubMed ID: 9574557
[TBL] [Abstract][Full Text] [Related]
35. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins.
Sung V; Stubbs JT; Fisher L; Aaron AD; Thompson EW
J Cell Physiol; 1998 Sep; 176(3):482-94. PubMed ID: 9699501
[TBL] [Abstract][Full Text] [Related]
36. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
Sheldrake HM; Patterson LH
J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of potent and selective inhibitors of integrin VLA-4.
Wattanasin S; Weidmann B; Roche D; Myers S; Xing A; Guo Q; Sabio M; von Matt P; Hugo R; Maida S; Lake P; Weetall M
Bioorg Med Chem Lett; 2001 Nov; 11(22):2955-8. PubMed ID: 11677134
[TBL] [Abstract][Full Text] [Related]
38. N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Chen L; Tilley JW; Guthrie RW; Mennona F; Huang TN; Kaplan G; Trilles R; Miklowski D; Huby N; Schwinge V; Wolitzky B; Rowan K
Bioorg Med Chem Lett; 2000 Apr; 10(8):729-33. PubMed ID: 10782674
[TBL] [Abstract][Full Text] [Related]
39. Structure and function of endothelial cell integrins.
Giltay JC; van Mourik JA
Haemostasis; 1988; 18(4-6):376-89. PubMed ID: 2466737
[TBL] [Abstract][Full Text] [Related]
40. The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor.
Perutelli P; Mori PG
Haematologica; 1992; 77(2):162-8. PubMed ID: 1383106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
